Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05257265 · ClinicalTrials.gov registry record · Phase 3
A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 459
- Enrollment target
NCT05257265 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 459 participants.
The verdict
NCT05257265, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 459 participants
- Enrollment target
Study Summary
This trial was conducted to evaluate the efficacy and safety of the Centanafadine once daily (QD) extended release (XR) capsules in adolescent participants (13 - 17 years, inclusive) with attention-deficit/hyperactivity disorder (ADHD).
Interventions
- OTHER Placebo
- DRUG Centanafadine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2023-10-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05257265
The ClinicalTrials.gov registry entry for NCT05257265 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 459 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05257265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05257265 about?
NCT05257265 is a clinical study titled "A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder". This trial was conducted to evaluate the efficacy and safety of the Centanafadine once daily (QD) extended release (XR) capsules in adolescent participants (13 - 17 years, inclusive) with attention-deficit/hyperactivity disorder (ADHD).
What is the current status of trial NCT05257265?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 459 participants. The study started on 2022-02-02. Estimated completion is 2023-10-05.
What interventions are being tested in trial NCT05257265?
The interventions under investigation include: Placebo (OTHER), Centanafadine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05257265?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.